{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:53Z","timestamp":1777934573509,"version":"3.51.4"},"reference-count":58,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Brazilian National Council for Scientific and Technological Development","award":["305508\/2020-2"],"award-info":[{"award-number":["305508\/2020-2"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cancer patients with Covid-19 are exposed to treatment combinations that can potentially result in interactions that adversely affect patient outcomes. This study aimed to identify potential drug\u2013drug interactions between antineoplastic agents and medicines used to treat Covid-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a search for potential interactions between 201 antineoplastic agents and 26 medicines used to treat Covid-19 on the Lexicomp\n                      <jats:sup>\u00ae<\/jats:sup>\n                      and Micromedex\n                      <jats:sup>\u00ae<\/jats:sup>\n                      databases. The following data were extracted: interaction severity (\u201cmajor\u201d and \u201ccontraindicated\u201d) and interaction effects (pharmacokinetic and pharmacodynamic). We also sought to identify the therapeutic indication of the antineoplastic drugs involved in the potential drug\u2013drug interactions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 388 \u201cmajor\u201d or \u201ccontraindicated\u201d drug\u2013drug interactions were detected. Eight drugs or combinations (baricitinib, lopinavir\/ritonavir, atazanavir, darunavir, azithromycin, chloroquine, hydroxychloroquine, and sirolimus) accounted for 91.5% of these interactions. The class of antineoplastic agents with the greatest potential for interaction was tyrosine kinase inhibitors (accounting for 46.4% of all interactions). The findings show that atazanavir, baricitinib, and lopinavir\/ritonavir can affect the treatment of all common types of cancer. The most common pharmacokinetic effect of the potential drug\u2013drug interactions was increased plasma concentration of the antineoplastic medicine (39.4%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Covid-19 is a recent disease and pharmacological interventions are undergoing constant modification. This study identified a considerable number of potential drug\u2013drug interactions. In view of the vulnerability of patients with cancer, it is vital that health professionals carefully assess the risks and benefits of drug combinations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211040494","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T21:18:01Z","timestamp":1634073481000},"page":"1737-1748","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Potential interactions between antineoplastic agents and medicines used to treat Covid-19"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0477-8595","authenticated-orcid":false,"given":"Mario Jorge","family":"Sobreira da Silva","sequence":"first","affiliation":[{"name":"National Cancer Institute of Brazil, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Garcia","family":"Serpa Osorio-de-Castro","sequence":"additional","affiliation":[{"name":"Sergio Arouca National School of Public Health, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael Duarte","family":"Paes","sequence":"additional","affiliation":[{"name":"Oncoclinicas of Brazil, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher Lucas","family":"Negrete","sequence":"additional","affiliation":[{"name":"S\u00edrio-Liban\u00eas Hospital, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizangela","family":"Eug\u00eanio","sequence":"additional","affiliation":[{"name":"AMO Clinic, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine Lazzaroni","family":"Moraes","sequence":"additional","affiliation":[{"name":"National Cancer Institute of Brazil, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemeri","family":"Livinalli","sequence":"additional","affiliation":[{"name":"CF Onco, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"bibr1-10781552211040494","unstructured":"Ferlay J, Laversanne M, Ervik M, et al. Global cancer observatory: cancer tomorrow. International Agency for Research on Cancer, https:\/\/gco.iarc.fr\/tomorrow (2020, accessed 05 February 2021)."},{"key":"bibr2-10781552211040494","doi-asserted-by":"publisher","DOI":"10.32635\/2176-9745.RBC.2020v66nTemaAtual.1077"},{"key":"bibr3-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31187-9"},{"key":"bibr4-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31173-9"},{"key":"bibr5-10781552211040494","volume":"66","author":"Thuler LCS","year":"2020","journal-title":"Rev Bras Cancerol"},{"key":"bibr6-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0941"},{"key":"bibr7-10781552211040494","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092452"},{"key":"bibr8-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01307"},{"key":"bibr9-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2020.1837946"},{"key":"bibr10-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc3208"},{"key":"bibr11-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008536"},{"key":"bibr12-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2980"},{"key":"bibr13-10781552211040494","unstructured":"American Society of Health-System Pharmacists. Assessment of evidence for COVID-19-related treatments, https:\/\/www.ashp.org\/-\/media\/assets\/pharmacy-practice\/resource-centers\/Coronavirus\/docs\/ASHP-COVID-19-Evidence-Table.ashx (2020, accessed 31 May 2020)."},{"key":"bibr14-10781552211040494","unstructured":"Gato MIR. MOC Drogas - Manual de oncologia cl\u00ednica do Brasil: agentes oncol\u00f3gicos. 9th ed. S\u00e3o Paulo: Dendrix Edi\u00e7\u00e3o e Design Ltda, 2020, p. 336."},{"key":"bibr15-10781552211040494","unstructured":"McEvoy GK and American Society of Health-System Pharmacists. AHFS Drug information 2008. 1st ed. Bethesda: American Society of Health-System Pharmacists, 2008, p. 3824."},{"key":"bibr16-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2009.10.011"},{"key":"bibr17-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00086"},{"key":"bibr18-10781552211040494","volume-title":"Lexi-drugs online","author":"Lexicomp I","year":"2021"},{"key":"bibr19-10781552211040494","volume-title":"IBM Micromedex\u00ae drug interaction checking (electronic version)","author":"Health IW","year":"2021"},{"key":"bibr20-10781552211040494","unstructured":"World Health Organization. Guidelines for ATC classification and DDD assignment. ATC\/DDD Index, https:\/\/www.whocc.no\/atc_ddd_index\/ (2021, accessed 05 February 2021)."},{"key":"bibr21-10781552211040494","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1133"},{"key":"bibr22-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102982"},{"key":"bibr23-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102991"},{"key":"bibr24-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031994"},{"key":"bibr25-10781552211040494","unstructured":"U.S. Food & Drug Administration. Coronavirus (COVID-19) update: FDA authorizes drug combination for treatment of COVID-19.\n                      FDA News Release\n                      , https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19 (2020, accessed 05 February 2021)."},{"key":"bibr26-10781552211040494","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1001\/jama.2019.20153","volume":"323","author":"Sanders JM","year":"2020","journal-title":"JAMA"},{"key":"bibr27-10781552211040494","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12090856"},{"key":"bibr28-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2438"},{"key":"bibr29-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3379"},{"key":"bibr30-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1010693107"},{"key":"bibr31-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1037"},{"key":"bibr32-10781552211040494","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212550"},{"key":"bibr33-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1232"},{"key":"bibr34-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2020.03.025"},{"key":"bibr35-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019833038"},{"key":"bibr36-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1586\/eri.11.48"},{"key":"bibr37-10781552211040494","doi-asserted-by":"publisher","DOI":"10.33448\/rsd-v9i8.6562"},{"key":"bibr38-10781552211040494","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00302"},{"key":"bibr39-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-020-00216-7"},{"key":"bibr40-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31863-8"},{"key":"bibr41-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2183"},{"key":"bibr42-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2335"},{"key":"bibr43-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2019.102822"},{"key":"bibr44-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105932"},{"key":"bibr45-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244778"},{"key":"bibr46-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.05.006"},{"key":"bibr47-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-180604"},{"key":"bibr48-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2020.06.001"},{"key":"bibr49-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-020-0153-3"},{"key":"bibr50-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj060428"},{"key":"bibr51-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.08.007"},{"key":"bibr52-10781552211040494","unstructured":"National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines, https:\/\/www.covid19treatmentguidelines.nih.gov\/whats-new\/ (2021, accessed 02 May 2021)."},{"key":"bibr53-10781552211040494","unstructured":"European Medicines Agency. COVID-19 treatments: authorised, https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/treatments-vaccines\/treatments-covid-19\/covid-19-treatments-authorised (2021, accessed 02 May 2021)."},{"key":"bibr54-10781552211040494","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria. Anvisa aprova registro da vacina da Fiocruz\/AstraZeneca e de medicamento contra o coronav\u00edrus, https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2021\/anvisa-aprova-registro-da-vacina-da-fiocruz-astrazeneca-e-de-medicamento-contra-o-coronavirus (2021, accessed 02 May 2021)."},{"key":"bibr55-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216682311"},{"key":"bibr56-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007724"},{"key":"bibr57-10781552211040494","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12030731"},{"key":"bibr58-10781552211040494","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.024"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211040494","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211040494","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211040494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:27Z","timestamp":1777688727000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211040494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1177\/10781552211040494"],"URL":"https:\/\/doi.org\/10.1177\/10781552211040494","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]}}}